Advisory Committee to the Director, Centers for Disease Control and Prevention, 7948-7949 [05-2961]

Download as PDF 7948 Federal Register / Vol. 70, No. 31 / Wednesday, February 16, 2005 / Notices practice of the Committee, the public notice, public comment, and delayed effective date provisions of the Administrative Procedure Act do not apply.3 For the reasons discussed above, the Committee has amended its Rules of Organization as follows: 1. Section 2(b) of the Rules of Organization is revised to read as follows: Section 2—Composition of Committee * * * * * (b) Reserve Bank representatives. The representatives of the Federal Reserve Banks, and an alternate for each representative, are elected by the boards of directors of the Reserve Banks in accordance with section 12A of the Federal Reserve Act (12 U.S.C. 263) for annual terms commencing on the date of the first regularly scheduled meeting of the Committee occurring on or after January 1 of each year. Prior to the first regularly scheduled meeting of the Committee on or after January 1 of each year, each member of the Committee representing the Federal Reserve Banks shall cause a record of the member’s election and of the election of the member’s alternate to be forwarded to the secretary of the Committee. If any question is raised as to the election or eligibility of a member or alternate, the Committee determines such question before such member or alternate participates in a meeting of the Committee. In the event a member is absent from a meeting of the Committee, the member’s alternate, in attending the meeting, shall have the same status as the member for whom the alternate is serving. If a member or alternate ceases to be a president or first vice president of a Reserve Bank, a successor may be chosen in a special election by the boards of directors of the appropriate Reserve Bank or Banks and such successor serves until the next annual election. * * * * * 2. The first sentence of § 3 of the Rules of Organization is revised to read as follows: Section 3—Chairman and Vice Chairman At its first regularly scheduled meeting on or after January 1 of each year, the Committee elects a chairman and a vice chairman from among its membership.* * * 3. Paragraphs (a) and (b) of § 4 of the Rules of Organization are revised to read as follows: 3 See 12:44 Feb 15, 2005 (a) Selection of staff officers. At its first regularly scheduled meeting on or after January 1 of each year, the Committee selects, from among the officers and employees of the Board and the Federal Reserve Banks, the following staff officers to serve until the first regularly scheduled meeting on or after January 1 of the next following year: secretary, deputy secretary, and one or more assistant secretaries; general counsel, deputy general counsel, and one or more assistant general counsels; economists, one or more of whom may be designated as senior or associate economists or given titles reflecting their areas of particular specialization; and such other officers as the Committee might wish from time to time. (b) Secretary and deputy and assistant secretaries. The secretary keeps minutes of actions and records of discussions at all meetings of the Committee; maintains a complete record of the actions taken by the Committee upon all questions of policy relating to open market operations; and records the votes taken in connection with the determination of open market policies and the reasons underlying each such action. The secretary has custody of such minutes and records, and performs such other duties as the Committee may require. In the absence of the secretary of the Committee, the deputy secretary or an assistant secretary acts as secretary pro tem. * * * * * 4. Section 5 of the Rules of Organization and its heading are revised to read as follows: Section 5—Manager The Committee selects a Manager of the System Open Market Account. The foregoing shall be satisfactory to the Federal Reserve Bank selected by the Committee to execute open market transactions for such Account and shall serve at the pleasure of the Committee. The Manager keeps the Committee informed on market conditions and on transactions made for such Account and renders such reports as the Committee may specify. By order of the Federal Open Market Committee, February 8, 2005. Vincent R. Reinhart, Secretary, Federal Open Market Committee. [FR Doc. 05–2776 Filed 2–15–05; 8:45 am] BILLING CODE 6210–01–P 5 U.S.C. 553(b) and (d). VerDate jul<14>2003 Section 4—Staff Jkt 205001 PO 00000 Frm 00027 Fmt 4703 Sfmt 4703 FEDERAL RETIREMENT THRIFT INVESTMENT BOARD Sunshine Act Meeting 9 a.m. (e.s.t.) February 22, 2005. PLACE: 4th Floor Conference Room, 1250 H Street, NW., Washington, DC. STATUS: Parts will be open to the public and parts closed to the public. MATTERS TO BE CONSIDERED: TIME AND DATE: Parts Open to the Public 1. Approval of the minutes of the January 19, 2005, Board member meeting. 2. Thrift Savings Plan activity report by the Executive Director. Parts Closed to the Public 3. Procurement. FOR FURTHER INFORMATION CONTACT: Thomas J. Trabucco, Director, Office of External Affairs, (202) 942–1640. Dated: February 14, 2005. Elizabeth S. Woodruff, Secretary to the Board, Federal Retirement Thrift Investment Board. [FR Doc. 05–3105 Filed 2–14–05; 3:00 pm] BILLING CODE 6760–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Advisory Committee to the Director, Centers for Disease Control and Prevention In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following Advisory Committee meeting. Name: Advisory Committee to the Director, CDC. Time and Date: 8:30 a.m.–4:30 p.m., March 3, 2005. Place: Centers for Disease Control and Prevention, Century Center Facility, 1825 Century Boulevard, NE., Atlanta, Georgia 30345, Rooms 1A and 1B. Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 65 people. Purpose: The committee will provide advice to the CDC Director on strategic and other broad issues facing CDC. Matters to be Discussed: Agenda items will include discussion of the CDC Futures Initiative and updates on CDC priorities with discussions of program E:\FR\FM\16FEN1.SGM 16FEN1 Federal Register / Vol. 70, No. 31 / Wednesday, February 16, 2005 / Notices activities including updates on CDC scientific and programmatic activities. Agenda items are subject to change as priorities dictate. FOR FURTHER INFORMATION CONTACT: Robert Delaney,Executive Secretary, Advisory Committee to the Director,CDC, 1600 Clifton Road, NE., M/S D–14, Atlanta, Georgia 30333. Telephone 404/639–7000. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Dated: February 10, 2005. Alvin Hall, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 05–2961 Filed 2–15–05; 8:45 am] BILLING CODE 4163–18–P Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panels: Occupational Health and Safety Research, Program Announcement (PA) 04038, and NIOSH Support for Conferences and Scientific Meetings, Program Announcement Request (PAR) 05005 In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting: Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panels (SEP): Occupational Health and Safety Research, Program Announcement 04038, and NIOSH Support for Conferences and Scientific Meetings, Program Announcement Request 05005. Times and Dates: 5 p.m.–5:30 p.m., March 9, 2005 (Open); 5:30 p.m.–7:30 p.m., March 9, 2005 (Closed); 8:30 a.m.–6:30 p.m., March 10, 2005 (Closed). Place: Royal Sonesta Hotel New Orleans, 300 Bourbon Street, New Orleans, LA 70140– 1014 telephone 504–586–0300. Status: Portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in 12:44 Feb 15, 2005 Jkt 205001 Dated: February 8, 2005. Alvin Hall, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention CDC. [FR Doc. 05–2963 Filed 2–15–05; 8:45 am] BILLING CODE 4163–19–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration DEPARTMENT OF HEALTH AND HUMAN SERVICES VerDate jul<14>2003 response to Program Announcement 04038 and Program Announcement Request 05005. Contact Person for More Information: Pamela J. Wilkerson, MPA, Scientific Review Administrator, Office of Extramural Programs, National Institute for Occupational Safety and Health, CDC, 1600 Clifton Road, NE., MS–E74, Atlanta, GA 30333, Telephone 404–498–2556. The Director, Management Analysis and Services Office has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the CDC and the Agency for Toxic Substances and Disease Registry. Cellular, Tissue and Gene Therapies Advisory Committee (formerly the Biological Response Modifiers Advisory Committee); Amendment of Notice AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Cellular, Tissue and Gene Therapies Advisory Committee (formerly the Biological Response Modifiers Advisory Committee). This meeting was announced in the Federal Register of January 27, 2005 (70 FR 3934). The amendment is being made to reflect the cancellation of the closed portion of the meeting and the following portions of the document: Date and Time, Agenda, Procedure, and Closed Committee Deliberations. There are no other changes. Gail Dapolito or Rosanna L. Harvey, Center for Biologics Evaluation and Research (HFM–71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–0314, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 3014512389. Please call the Information Line for up-to-date information on this meeting. SUPPLEMENTARY INFORMATION: In the Federal Register of January 27, 2005, FOR FURTHER INFORMATION CONTACT: PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 7949 FDA announced that a meeting of the Cellular, Tissue and Gene Therapies Advisory Committee (formerly the Biological Response Modifiers Advisory Committee) would be held on March 3 and 4, 2005. On page 3935, in the first column, the introductory paragraph, Date and Time, Agenda, and Procedure portions of the document are amended to read as follows: This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public. Date and Time: The meeting will be held on March 3, 2005, from 8 a.m. to approximately 6 p.m. and on March 4, 2005, from 8 a.m. to approximately 5 p.m. Agenda: On March 3, 2005, all day and on March 4, 2005, in the morning, the committee will discuss cellular therapies for repair and regeneration of joint surfaces. Additionally, on March 4, 2005, the committee will discuss safety issues related to retroviral vectormediated tumorigenesis in gene transfer clinical trials. Procedure: On March 3, 2005, from 8 a.m. to approximately 6 p.m. and on March 4, 2005, from 8 a.m. to approximately 5 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by February 23, 2005. Oral presentations from the public will be scheduled on March 3, 2005, between approximately 11 a.m. and 11:30 a.m. and on March 4, 2005, between approximately 12 noon and 12:30 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before February 23, 2005, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. On page 3935, in the second column, the Closed Committee Deliberations portion of the document is deleted to reflect the cancellation of the closed portion of the meeting on March 3, 2005. This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees. E:\FR\FM\16FEN1.SGM 16FEN1

Agencies

[Federal Register Volume 70, Number 31 (Wednesday, February 16, 2005)]
[Notices]
[Pages 7948-7949]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-2961]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Advisory Committee to the Director, Centers for Disease Control 
and Prevention

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following Advisory Committee meeting.
    Name: Advisory Committee to the Director, CDC.
    Time and Date: 8:30 a.m.-4:30 p.m., March 3, 2005.
    Place: Centers for Disease Control and Prevention, Century Center 
Facility, 1825 Century Boulevard, NE., Atlanta, Georgia 30345, Rooms 1A 
and 1B.
    Status: Open to the public, limited only by the space available. 
The meeting room accommodates approximately 65 people.
    Purpose: The committee will provide advice to the CDC Director on 
strategic and other broad issues facing CDC.
    Matters to be Discussed: Agenda items will include discussion of 
the CDC Futures Initiative and updates on CDC priorities with 
discussions of program

[[Page 7949]]

activities including updates on CDC scientific and programmatic 
activities.
    Agenda items are subject to change as priorities dictate.

FOR FURTHER INFORMATION CONTACT: Robert Delaney,Executive Secretary, 
Advisory Committee to the Director,CDC, 1600 Clifton Road, NE., M/S D-
14, Atlanta, Georgia 30333. Telephone 404/639-7000.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities, 
for both CDC and the Agency for Toxic Substances and Disease Registry.

    Dated: February 10, 2005.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 05-2961 Filed 2-15-05; 8:45 am]
BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.